News

Early Trial Supporting 3-month Dosing With STAR-0215 for HAE

A single injection of STAR-0215, an experimental treatment to prevent swelling attacks in people with hereditary angioedema (HAE), safely led to rapid and sustained inhibition of the kallikrein protein in healthy adults, according to preliminary data from a Phase 1a trial. “STAR-0215 has shown early proof of concept for…

Israel Approves Oral Therapy Orladeyo to Prevent HAE Attacks

Adult and adolescent patients, ages 12 and older, with hereditary angioedema (HAE)  in Israel can now receive once-daily Orladeyo (berotralstat) to prevent HAE-related swelling attacks. The decision to approve the medication by the Israeli Ministry of Health follows similar decisions in Canada and Switzerland, as well as…

Most HAE Patients Treated With Donidalorsen for Year Attack Free

Donidalorsen, a small molecule therapy being developed by Ionis Pharmaceuticals, continues to be safe and to prevent swelling attacks when taken for up to one year by people with hereditary angioedema (HAE), trial data show. The open-label extension study (NCT04307381) is ongoing in patients who completed a placebo-controlled…

Single-dose PHA121 Shows Promise in Trial as Treatment for HAE

A single dose of the extended-release formulation of PHA121 — an investigational molecule under development for the prevention and treatment of swelling attacks associated with hereditary angioedema (HAE) — led to sustained, therapeutic levels of the medication in the bloodstream of participants. That’s according to promising data from…